UC Riverside Study Links 2 Alzheimer’s Proteins to Early Cell Damage
Updated
Updated · Newsweek · Jun 19
UC Riverside Study Links 2 Alzheimer’s Proteins to Early Cell Damage
2 articles · Updated · Newsweek · Jun 19
Summary
UC Riverside researchers found amyloid beta and tau compete for the same microtubule binding sites inside neurons, a mechanism they say could disrupt cell transport before brain plaques become the main problem.
Fluorescent tracking showed amyloid beta can bind microtubules with strength similar to tau, potentially displacing tau from its normal role and destabilizing the cell’s internal machinery.
The study argues this intracellular clash may help explain why thousands of plaque-targeting Alzheimer’s trials have largely failed to stop or reverse disease progression.
Age-related decline in autophagy could let amyloid beta accumulate inside neurons, increasing the chance of that competition and linking aging to an earlier stage of disease development.
Researchers and outside clinicians called the mechanism biologically plausible but still unproven in patients, saying the next step is to confirm whether it tracks with memory loss and decline in people.
After decades of failed trials, does this new theory reveal the real culprit behind Alzheimer's disease?
If Alzheimer's starts inside cells, why do new plaque-busting drugs show any clinical promise at all?
Unifying Alzheimer’s Disease: The Protein Competition Theory and Its Implications for Early Detection and Therapy
Overview
UC Riverside scientists introduced the Protein Competition Theory, offering a new explanation for Alzheimer’s disease. Instead of blaming amyloid-beta plaques or tau tangles alone, this theory shows that both proteins compete for the same spots on neuronal microtubules. As amyloid-beta builds up, it pushes tau away from these sites, disrupting the cell’s transport system. This early disruption leads to the damage seen in Alzheimer’s, making plaques and tangles a result, not the cause. This new view connects previous research gaps and suggests that protecting microtubules could be key to better treatments.